Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.